Quantitative Proteomics on Immune Cells of ME/CFS Patients Using SWATH-MS.
Kumar, Abhishek, Peppercorn, Katie, Kleffmann, Torsten · Methods in molecular biology (Clifton, N.J.) · 2025 · DOI
Quick Summary
This study describes a detailed scientific method for examining proteins in immune cells taken from the blood of ME/CFS patients. Researchers used advanced technology called SWATH-MS (a type of mass spectrometry) to identify and measure thousands of proteins at once. The paper explains the step-by-step process they used so that other researchers can use the same method to find protein abnormalities in ME/CFS.
Why It Matters
ME/CFS lacks clear diagnostic biomarkers, and understanding protein abnormalities in immune cells is critical for uncovering disease mechanisms. By providing a standardized, detailed methodology that other laboratories can implement, this work enables consistent, comparable proteomic research across institutions. This could accelerate the discovery of protein-based biomarkers for diagnosis and potentially identify new treatment targets.
Observed Findings
The study demonstrates successful SWATH-MS workflow implementation for PBMC proteomics analysis
Both library-based (PeakView/MarkerView) and library-free (DIA-NN) analytical pipelines are viable for this application
Comprehensive spectral library generation from pre-fractionated peptide reference samples enables robust protein quantification
Data-independent acquisition provides reproducible quantitative protein profiling across individual patient samples
Inferred Conclusions
SWATH-MS is a feasible, quantitative proteomics approach for investigating immune cell protein alterations in ME/CFS
Multiple software analysis pipelines (both commercial and open-source) can effectively process SWATH-MS data from ME/CFS samples
Standardized, detailed protocols are necessary for consistent proteomics studies across research institutions
Remaining Questions
Which specific proteins show significant alterations in ME/CFS patients compared to healthy controls or other disease states?
How do the two analytical pipelines (commercial vs. open-source) compare in sensitivity, specificity, and reproducibility for detecting disease-relevant protein changes?
Can proteomic signatures identified through this workflow serve as diagnostic or prognostic biomarkers for ME/CFS?
What This Study Does Not Prove
This is a methods paper, not a clinical study, so it does not report actual findings about which specific proteins are abnormal in ME/CFS patients or prove that any particular protein causes or contributes to the disease. The paper does not establish disease mechanisms or validate biomarkers. It also does not compare ME/CFS patients to healthy controls or other patient groups.